XERS — Xeris Biopharma Holdings, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1867096 ·
Last close
$6.26
Market Cap
$1.08B
52W High
$7.12
52W Low
$5.25
ADV30
1,575,572
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 83,127,000 | 72,553,000 | 7,916,000 | 2,234,000 | 392,013,000 | 111,750,000 | 379,002,000 |
| Dec 2025 | 85,807,000 | 74,860,000 | 16,773,000 | 11,081,000 | 383,527,000 | 111,042,000 | 369,838,000 |
| Sep 2025 | 74,380,000 | 63,384,000 | 6,731,000 | 621,000 | 370,191,000 | 91,598,000 | 371,052,000 |
| Jun 2025 | 71,539,000 | 59,641,000 | 4,482,000 | -1,928,000 | 334,686,000 | 59,285,000 | 353,990,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$28,626,000
Investing CF
$-696,000
Financing CF
$11,389,000
CapEx
$-696,000
Dividends Paid
—
Buybacks
$-10,876,000
EPS Diluted TTM
$-0.01
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-671,307,000
Inventory
$68,673,000
Receivables
$51,050,000
ST Investments
$0
EBIT TTM
$29,638,000
Pretax Income TTM
$554,000
Interest Exp TTM
$29,084,000
Analysts
7
Yahoo Snapshot (yfinance, live)
Total Revenue
$314,852,992
EBITDA
$48,080,000
Free Cash Flow
$42,205,376
Enterprise Value
$1,215,457,280
Total Cash
$111,750,000
Total Debt
$258,552,992
Shares Out
172,642,055
Trailing EPS
$0.07
Book Value
$0.08
ROE
—
ROA
6.3%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 291,845,000 | 24,896,000 | 554,000 | 383,527,000 | 369,838,000 | — | 28,626,000 |
| Dec 2024 | 203,070,000 | -33,646,000 | -54,836,000 | 323,060,000 | 352,675,000 | — | -36,981,000 |
| Dec 2023 | 163,914,000 | -44,010,000 | -62,255,000 | 322,602,000 | 329,384,000 | — | -47,023,000 |
| Dec 2022 | 110,248,000 | -81,940,000 | -94,660,000 | 344,522,000 | 299,335,000 | — | -102,891,000 |
TTM Snapshot
Revenues TTM
$143,373,000
NetIncome TTM
$-75,767,000
OpCashFlow TTM
$0
Assets (Latest)
$323,060,000
Forward EPS
$0.40
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CRVS | Corvus Pharmaceuticals, Inc. | $1.08B | $12.83 | — |
| IVA | Inventiva S.A. | $1.08B | $5.16 | — |
| JBIO | Jade Biosciences, Inc. | $1.07B | $21.71 | — |
| MNKD | MANNKIND CORP | $1.09B | $3.53 | — |
| COLL | COLLEGIUM PHARMACEUTICAL, INC | $1.10B | $33.78 | — |
News headlines (Yahoo Finance, 1h cache)
Shareholders Will Be Pleased With The Quality of Xeris Biopharma Holdings' (NASDAQ:XERS) Earnings
2026-05-15 11:49 · Yahoo
Results: Xeris Biopharma Holdings, Inc. Confounded Analyst Expectations With A Surprise Profit
2026-05-09 14:19 · Yahoo
Xeris Biopharma Q1 Earnings Call Highlights
2026-05-09 08:07 · Yahoo
Xeris Biopharma Holdings, Inc. Q1 2026 Earnings Call Summary
2026-05-08 12:30 · Yahoo
Xeris Biopharma Holdings (XERS) Is Up 8.2% After Swing to Q1 Profitability - What's Changed
2026-05-08 09:13 · Yahoo
Xeris (XERS) Q1 2026 Earnings Call Transcript
2026-05-07 20:13 · Yahoo
Xeris Biopharma (XERS) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
2026-05-07 13:30 · Yahoo
Xeris Biopharma Reports First Quarter 2026 Financial Results
2026-05-07 11:00 · Yahoo
Xeris Biopharma to Report First Quarter 2026 Financial Results on May 7, 2026
2026-04-23 11:30 · Yahoo
Does Record Q4 Results, Robust 2026 Guidance and Recorlev Patent Suit Change The Bull Case For Xeris (XERS)?
2026-04-13 13:07 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.